Cefepime
Cefepime, Exblifep (cefepime) is a small molecule pharmaceutical. Cefepime was first approved as Maxipime on 1996-01-18. It is used to treat acinetobacter infections, bacterial infections, bacterial pneumonia, bacterial skin diseases, and bacteroides infections amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Cefepime (discontinued: Cefepime, Maxipime)
CombinationsZaynich
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cefepime hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER | B. Braun Medical | N-050821 RX | 2010-05-06 | 2 products, RLD, RS |
| CEFEPIME IN PLASTIC CONTAINER | Baxter | N-050817 RX | 2008-08-05 | 2 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cefepime | ANDA | 2026-08-03 |
| cefepime cefepime | ANDA | 2023-09-30 |
| cefepime hydrochloride | ANDA | 2025-10-14 |
| cefepime hydrochloride and dextrose | New Drug Application | 2026-04-07 |
| zaynich | New Drug Application | 2026-06-05 |
Indications
FDA
EMA
Show 10 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
Clinical
Clinical Trials
113 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | — | 2 | 6 | 3 | 9 | 20 |
| Neutropenia | D009503 | — | D70 | 1 | 2 | 2 | 4 | 4 | 13 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | — | 2 | 3 | 7 | 12 |
| Communicable diseases | D003141 | — | — | — | 2 | 4 | 1 | 5 | 12 |
| Febrile neutropenia | D064147 | — | — | — | 2 | 1 | 5 | 3 | 11 |
| Sepsis | D018805 | EFO_0001420 | A41.9 | — | — | — | 3 | 8 | 11 |
| Fever | D005334 | — | R50.9 | — | 2 | 2 | 3 | 2 | 9 |
| Bacterial infections | D001424 | — | A49 | 2 | 1 | 1 | 2 | 2 | 8 |
| Hyperthermia | D000084462 | — | — | — | 2 | 1 | 2 | 2 | 7 |
| Bacteremia | D016470 | EFO_0003033 | R78.81 | — | — | 1 | 1 | 5 | 7 |
Show 24 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | 4 | 9 | — | 5 | 18 |
| Pyelonephritis | D011704 | EFO_1001141 | N10-N16 | — | — | 6 | — | — | 6 |
| Septic shock | D012772 | — | A48.3 | — | — | 1 | — | 2 | 3 |
| Healthcare-associated pneumonia | D000077299 | — | — | — | — | 1 | — | 2 | 3 |
| Pseudomonas infections | D011552 | EFO_0001076 | A41.52 | — | 2 | 1 | — | — | 3 |
| Enterobacteriaceae infections | D004756 | EFO_1001313 | — | — | 1 | 1 | — | — | 2 |
| Respiratory tract infections | D012141 | — | J06.9 | — | — | 1 | — | 1 | 2 |
| Intraabdominal infections | D059413 | — | — | — | — | 1 | — | 1 | 2 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | — | 1 | — | — | 2 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | — | 1 | — | — | 2 |
Show 36 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Methicillin-resistant staphylococcus aureus | D055624 | — | — | — | 1 | — | — | 1 | 2 |
| Pseudomonas aeruginosa | D011550 | NCBITaxon_287 | — | — | 2 | — | — | — | 2 |
| Gastrointestinal microbiome | D000069196 | — | — | — | 1 | — | — | — | 1 |
| Reinfection | D000084063 | — | — | — | 1 | — | — | — | 1 |
| Anaphylaxis | D000707 | — | T78.2 | — | 1 | — | — | — | 1 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | 1 | — | — | — | 1 |
| Drug hypersensitivity | D004342 | EFO_0009482 | T88.7 | — | 1 | — | — | — | 1 |
| Cephalosporin resistance | D018550 | — | Z16.19 | — | 1 | — | — | — | 1 |
| Escherichia coli infections | D004927 | EFO_1001318 | B96.20 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 5 | — | — | — | — | 5 |
| Renal insufficiency | D051437 | — | N19 | 3 | — | — | — | — | 3 |
| Pharmacokinetics | D010599 | — | — | 2 | — | — | — | 1 | 3 |
| Gram-negative bacterial infections | D016905 | — | — | 1 | — | — | — | 1 | 2 |
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | — | — | — | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
| Primary myelofibrosis | D055728 | — | D47.4 | 1 | — | — | — | — | 1 |
| Multiple myeloma | D009101 | — | C90.0 | 1 | — | — | — | — | 1 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 1 | — | — | — | — | 1 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 1 | — | — | — | — | 1 |
Show 8 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 2 | 2 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | — | — | 2 | 2 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 2 | 2 |
| Menorrhagia | D008595 | EFO_0003945 | N92.0 | — | — | — | — | 2 | 2 |
| Hemophilia a | D006467 | EFO_0007267 | D66 | — | — | — | — | 2 | 2 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 2 | 2 |
| Hyperaldosteronism | D006929 | — | E26 | — | — | — | — | 2 | 2 |
| Pulmonary arterial hypertension | D000081029 | — | — | — | — | — | — | 2 | 2 |
| Hypokalemia | D007008 | — | E87.6 | — | — | — | — | 2 | 2 |
| Sleep initiation and maintenance disorders | D007319 | — | F51.01 | — | — | — | — | 2 | 2 |
Show 64 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Cefepime |
| INN | cefepime |
| Description | Cefepime is a cephalosporin bearing (1-methylpyrrolidinium-1-yl)methyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It has a role as an antibacterial drug. It is a cephalosporin and an oxime O-ether. It is a conjugate base of a cefepime(1+). |
| Classification | Small molecule |
| Drug class | cephalosporins |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[N+]3(C)CCCC3)CS[C@H]12)c1csc(N)n1 |
Identifiers
| PDB | — |
| CAS-ID | 88040-23-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL186 |
| ChEBI ID | 478164 |
| PubChem CID | 5479537 |
| DrugBank | DB01413 |
| UNII ID | 807PW4VQE3 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Maxipime – Elan Corporation
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,999 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
7,690 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use